Implementation of Evidence-Based Strategy (PC TEACH) for the Optimization of HPV Vaccination in Rural Primary Care
Launched by ROSWELL PARK CANCER INSTITUTE · Feb 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called PC TEACH, is focused on improving the rates of Human Papillomavirus (HPV) vaccinations in rural primary care settings. The goal is to find better ways to encourage and support vaccination against HPV, which can help prevent certain types of cancer. Many rural communities have lower vaccination rates, so this study aims to identify and use effective strategies to ensure more young people receive the vaccine. By working closely with medical providers and staff in these communities, the trial hopes to enhance access to and awareness of HPV vaccination.
To be eligible for this study, practices need to be located in a specific 20-county area and have at least 150 adolescent patients aged 9 to 18 who receive vaccines. Medical providers and staff who are 18 years or older and speak English can participate, as well as parents or guardians of children aged 9 to 17 who are visiting the clinic for routine checkups. Participants can expect to contribute by filling out anonymous surveys during their clinic visits, helping to gather valuable information on improving vaccination efforts. This trial is a great opportunity for rural communities to work toward better health outcomes for their youth.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • PRACTICES: Are located in the 20-county target region
- • PRACTICES: Have an adolescent patient population \>= 150 (aged 9-18)
- • PRACTICES: Administer adolescent vaccines (e.g., HPV, Tdap, MCV4)
- • PRACTICES: Are willing to share aggregate practice and patient-level data (e.g., electronic health record \[EHR\], surveys)
- • PARTICIPANTS: Medical providers and medical staff \>= 18 years of age
- • PARTICIPANTS: Primary care providers and medical office staff who deliver adolescent care at community-based primary care practice sites across 20 rural counties in central and western New York
- • PARTICIPANTS: Age \>= 18 years of age (no upper limit)
- • PARTICIPANTS: English speaking
- • PARENT/GUARDIAN SURVEY: Adult accompanying a child or children aged 9 to 17
- • PARENT/GUARDIAN SURVEY: English speaking
- • PARENT/GUARDIAN SURVEY: Presenting to the participating clinic for an outpatient well child visit or regular checkup
- • PARENT/GUARDIAN SURVEY: Willing to complete an anonymous survey while visiting the clinic
- Exclusion Criteria:
- • Unwilling or unable to follow protocol requirements
- • Adults unable to complete study measures in English
- • Individuals who are not yet adults (infants, children, teenagers)
- • Cognitively impaired adults/adults with impaired decision-making capacity
- • Prisoners
About Roswell Park Cancer Institute
Roswell Park Cancer Institute is a leading biomedical research and treatment center dedicated to advancing cancer care through innovative research, education, and patient-centered clinical services. Established in 1898, it is recognized for its pioneering contributions to cancer research and treatment, making significant strides in immunotherapy, precision medicine, and cancer prevention. With a commitment to translating scientific discoveries into effective therapies, Roswell Park conducts a wide range of clinical trials aimed at improving outcomes for cancer patients. Its multidisciplinary team of experts collaborates to provide comprehensive care while fostering an environment of discovery and hope for patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Buffalo, New York, United States
Patients applied
Trial Officials
Elisa Rodriguez
Principal Investigator
Roswell Park Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported